AON-MB23 / Kolon Life Sci - LARVOL DELTA

Kolon Pharmaceutical and Estrion Jointly Develop New Drug for Triple Negative Breast Cancer [Google translation] (Hankyung) - "Kolon Pharmaceutical announced on the 9th that it signed a joint research and development agreement with small molecule new drug development research company Estrion for the new drug development project of 'AON-MB23', a triple-negative breast cancer treatment candidate. The two companies also joined hands in March of this year for the joint development of a glioblastoma treatment....The results of the joint research with Kolon Pharmaceutical are expected to be available around 2027. The goal is to submit a Phase 1 clinical trial plan (IND) to the FDA at that time."

IND • Licensing / partnership • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer